Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Stargardt's Disease
- Main trialPhase 2
- “Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: * Safety * Biological activity”In the company’s words, NCT01736592 on ClinicalTrials.gov
Other drugs for Stargardt's Disease
Coming up1
- 29 Aug 2033Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 29 Aug 2033 | Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration | |
| Phase 1/2Terminated | 16 Aug 2019 | Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026